The Evanston college claims Moderna could not have developed the vaccine as quickly as it did in 2020 without its own ...

Discover why the stock prices of mRNA therapy creators BioNTech and Moderna have plummeted and whether they are still worth ...

Considering the reasons behind the jump in licensing deal values, Chan added: “Licensing agreement deal values for mRNA-based ...

As the COVID virus continues to evolve, experts in respiratory diseases recommend that everyone ages 6 months and older ...

The XEC variant of Covid is quickly becoming the dominant strain of the winter, but the current vaccines may not be as ...

Even previous versions of the vaccine built from XEC’s predecessors like omicron might not be as effective against the new ...

The vaccine that’s helped protect millions of people worldwide from the COVID-19 virus and its variants would not have been ...

Benzinga examined the prospects for many investors’ favorite stocks over the last week — here’s a look at some of our top stories.

Rosen Law Firm, a global investor rights law firm, reminds purchasers of stock of Metagenomi, Inc. (NASDAQ: MGX) pursuant and/or traceable to the Company's initial public offering conducted between ...

Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Metagenomi To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $50,000 in ...

We recently published a list of 10 Best Medical Stocks to Buy Now. In this article, we are going to take a look at where ...